# VRDN catalysts: Viridian Therapeutics, Inc.\DE PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/vrdn/catalysts

> Viridian Therapeutics, Inc.\DE (VRDN) has 4 upcoming catalysts. The next is the elegrobart NDA/BLA submission, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for VRDN?

Viridian Therapeutics, Inc.\DE (VRDN) has 4 upcoming catalysts. The next is the elegrobart NDA/BLA submission, Q1 2027. Press release filed with the SEC (EX-99): "Our pipeline also continues to move forward as we advance elegrobart, our subcutaneously administered anti-IGF-1R, toward a planned BLA submission for TED in the first quarter of 2027." [Calendar and source filings](https://sec-api.dev/companies/vrdn/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-446200, https://www.sec.gov/Archives/edgar/data/1590750/000119312526446200/d176865dex991.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/companies/vrdn/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Viridian Therapeutics, Inc.\DE |
| Ticker | VRDN (Nasdaq) |
| SEC CIK | 1590750 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/vrdn |

## Cash runway

Cash $955.2M as of 2026-09-30; quarterly burn $92.8M; about 30.9 months of runway at that rate (XBRL company facts, accession 0001590750-26-000022).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2022 | [Lumvoa™ (veligrotug) trial start](https://sec-api.dev/pdufa/veligrotug) | VRDN |  | completed | "In May 2022, the Company paid a $3.0 million milestone payment to ImmunoGen related to the first patient dosed in the clinical trial for veligrotug." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1590750/000159075025000012/vrdn-20250630.htm)) |
| Dec 2022 | [Lumvoa™ (veligrotug) trial start](https://sec-api.dev/pdufa/veligrotug) | VRDN |  | completed | "In December 2022, the Company recorded $10.0 million as research and development expense related to a milestone owed to ImmunoGen related to the first patient dosed in a pivotal clinical trial for veligrotug, which was paid in January 2023." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1590750/000159075025000012/vrdn-20250630.htm)) |
| Sep 2024 | [Viridian Therapeutics, Inc.\DE topline data readout](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed, positive | "We reported positive topline THRIVE and THRIVE-2 data in September 2024 and December 2024, respectively." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm)) |
| late 2024 | [Lumvoa™ (veligrotug) topline data readout](https://sec-api.dev/pdufa/veligrotug) | VRDN |  | scheduled | "We completed enrollment of THRIVE-2 in July 2024, and expect to announce topline data for this study by the end of 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1590750/000159075024000023/vrdn-20240930.htm)) |
| November 12, 2024 | [Viridian Therapeutics, Inc.\DE earnings report](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed | "Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312524255130/d911553dex991.htm)) |
| Dec 2024 | [Viridian Therapeutics, Inc.\DE topline data readout](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed, positive | "In December 2024, we announced positive topline data from THRIVE-2." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm)) |
| Dec 2024 | [VRDN-006 NDA/BLA submission](https://sec-api.dev/pdufa/vrdn-006) | VRDN |  | completed | "We submitted an Investigational New Drug Application ("IND") for VRDN-006 in December 2024, which cleared in January 2025, and we expect proof-of-concept IgG reduction data in healthy volunteers in the third quarter of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1590750/000159075025000004/vrdn-20241231.htm)) |
| December 16, 2024 | [Lumvoa™ (veligrotug) topline data readout](https://sec-api.dev/pdufa/veligrotug) | VRDN | chronic TED | completed, positive | "WALTHAM, Mass., December 16, 2024  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312524279021/d648282dex991.htm)) |
| early 2025 | [VRDN-006 trial start](https://sec-api.dev/pdufa/vrdn-006) | VRDN |  | scheduled | "Viridian anticipates starting a phase 1 clinical trial for VRDN-006 in healthy volunteers in early 2025 and proof-of-concept IgG reductions from that study in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312524255130/d911553dex991.htm)) |
| February 27, 2025 | [Viridian Therapeutics, Inc.\DE earnings report](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed | "Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312525037586/d865236dex991.htm)) |
| May 1, 2025 | [Lumvoa™ (veligrotug) primary completion](https://sec-api.dev/pdufa/veligrotug) | VRDN | Thyroid Eye Disease | completed | "NCT06384547 (A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-01 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.; Results First Posted 2026-08-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06384547)) |
| May 6, 2025 | [Viridian Therapeutics, Inc.\DE earnings report](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed | "Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312525113291/d937417dex991.htm)) |
| Q3 2025 | [VRDN-006 topline data readout](https://sec-api.dev/pdufa/vrdn-006) | VRDN |  | scheduled | "preclinical development, clinical development, and anticipated commercialization of Viridians product candidates veligrotug (formerly VRDN-001), VRDN-003, VRDN-006, and VRDN-008; anticipated data results and timing of their disclosure, including VRDN-003 topline data from the REVEAL-1 and REVEAL-2 trials in the first half of 2026 and anticipated VRDN-006 clinical data, including proof-of-concept IgG reduction data, in the third quarter of 2025; regulatory interactions and anticipated timing of regulatory submissions, including the anticipated" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312525173983/d20477dex991.htm)) |
| August 6, 2025 | [Viridian Therapeutics, Inc.\DE earnings report](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed | "Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312525173983/d20477dex991.htm)) |
| late 2025 | [Elegrobart NDA/BLA submission](https://sec-api.dev/pdufa/elegrobart) | VRDN |  | scheduled | "REVEAL-1 in Q1 2026 and REVEAL-2 in Q2 2026; VRDN-003 BLA submission planned for year-end" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312525265711/d33707dex991.htm)) |
| late 2025 | [VRDN-008 NDA/BLA submission](https://sec-api.dev/pdufa/vrdn-008) | VRDN |  | scheduled | "•the timing and focus of our ongoing and future nonclinical studies and clinical trials and the timing of reporting data from those studies and trials, including that we anticipate submitting an Investigational New Drug Application ("IND") for VRDN-008 by the end of 2025;" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1590750/000159075025000020/vrdn-20250930.htm)) |
| November 5, 2025 | [Viridian Therapeutics, Inc.\DE earnings report](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed | "Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312525265711/d33707dex991.htm)) |
| 1H 2026 | [Viridian Therapeutics, Inc.\DE topline data readout](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | scheduled | "Topline Data from Phase 3 Clinical Trials On Track for 1H 2026: Viridian anticipates topline data from both REVEAL-1 and REVEAL-2 in the first half of 2026, with a BLA submission planned by year-end 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312525113291/d937417dex991.htm)) |
| Jan 2026 | [VRDN-008 trial start](https://sec-api.dev/pdufa/vrdn-008) | VRDN |  | completed | "VRDN-008 IND was accepted by the FDA in January 2026, and Viridian initiated a phase 1 clinical trial in healthy volunteers which is ongoing." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526205010/d149508dex991.htm)) |
| Q1 2026 | [Viridian Therapeutics, Inc.\DE topline data readout](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | scheduled | "REVEAL-1 topline data in active TED on track for Q1 2026 and REVEAL-2 topline data in chronic TED on track for Q2" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526073391/d105707dex991.htm)) |
| Q1 2026 | [Lumvoa™ (veligrotug) NDA/BLA submission](https://sec-api.dev/pdufa/veligrotug) | VRDN |  | scheduled | "•the timing or likelihood of regulatory filings and approvals, including the anticipated filing and approval of the biologics license application ("BLA") by FDA for veligrotug and submission of a Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA") in the first quarter of 2026, as well as our expectation that Breakthrough Therapy Designation may support eligibility for and potential receipt of Priority Review of our BLA, and our expectation to seek an accelerated approval pathway and special designations for our product candidates for various diseases;" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1590750/000159075025000020/vrdn-20250930.htm)) |
| February 12, 2026 | [VRDN-003 primary completion](https://sec-api.dev/pdufa/vrdn-003) | VRDN | Thyroid Eye Disease | completed | "NCT06625411 (An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-12 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06625411)) |
| February 26, 2026 | [Viridian Therapeutics, Inc.\DE earnings report](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed | "Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526073391/d105707dex991.htm)) |
| March 4, 2026 | [VRDN-003 primary completion](https://sec-api.dev/pdufa/vrdn-003) | VRDN | Thyroid Eye Disease | completed | "NCT06625398 (An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-04 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06625398)) |
| March 30, 2026 | [Elegrobart topline data readout](https://sec-api.dev/pdufa/elegrobart) | VRDN |  | completed, positive | "WALTHAM, Mass. - March 30, 2026—Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced positive topline data from the elegrobart REVEAL-1 phase 3 clinical trial in patients with active thyroid eye disease (TED)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526130433/d27955dex991.htm)) |
| Q2 2026 | [Elegrobart topline data readout](https://sec-api.dev/pdufa/elegrobart) | VRDN | chronic TED | scheduled | "- REVEAL-2, a phase 3 clinical trial evaluating elegrobart in patients with chronic TED, is on track for topline readout in Q2 2026; BLA submission anticipated in Q1 2027 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526130433/d27955dex991.htm)) |
| April 22, 2026 | [VRDN-003 primary completion](https://sec-api.dev/pdufa/vrdn-003) | VRDN | Thyroid Eye Disease (TED) | completed | "NCT06812325 (A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-22 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06812325)) |
| May 5, 2026 | [Viridian Therapeutics, Inc.\DE earnings report](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed | "Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526205010/d149508dex991.htm)) |
| May 5, 2026 | [Elegrobart topline data readout](https://sec-api.dev/pdufa/elegrobart) | VRDN |  | completed, positive | "WALTHAM, Mass. - (BUSINESS WIRE) - Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced positive topline data from the REVEAL-2 phase 3 clinical trial of elegrobart in patients with chronic thyroid eye disease (TED)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526205099/d20977dex991.htm)) |
| May 28, 2026 | [VRDN-003 primary completion](https://sec-api.dev/pdufa/vrdn-003) | VRDN | Thyroid Eye Disease | completed | "NCT07155668 (A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-28 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07155668)) |
| June 26, 2026 | [Lumvoa™ (veligrotug) FDA approval](https://sec-api.dev/pdufa/veligrotug) | VRDN | thyroid eye disease | completed, approved | "On June 26, 2026, Viridian Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease ("TED") regardless of activity or duration." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1590750/000119312526286273/d164211d8k.htm)) |
| June 26, 2026 | [Lumvoa™ (veligrotug) PDUFA date](https://sec-api.dev/pdufa/veligrotug) | VRDN |  | completed, approved | "- Lumvoa (veligrotug-vvze) approved by the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of target PDUFA date and immediately launched in the U.S. -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526336691/d174744dex991.htm)) |
| June 26, 2026 | [Lumvoa (veligrotug-vvze) FDA approval](https://sec-api.dev/pdufa/veligrotug-vvze) | VRDN | To treat thyroid eye disease | completed, approved | "Lumvoa \| veligrotug-vvze \| 6/26/2026 \| To treat thyroid eye disease" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| June 30, 2026 | [Lumvoa™ (veligrotug) topline data readout](https://sec-api.dev/pdufa/veligrotug) | VRDN |  | scheduled | "FDA, with PDUFA target date of June 30, 2026 Topline results reported December 2024 Met all primary & secondary endpoints Topline results reported September 2024 Met all primary & secondary endpoints Veligrotug met the primary and all secondary endpoints with statistical significance in two phase 3 trials, THRIVE and THRIVE-2" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526130433/d27955dex992.htm)) |
| June 30, 2026 | [Lumvoa™ (veligrotug) PDUFA date](https://sec-api.dev/pdufa/veligrotug) | VRDN |  | completed, approved | "- PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease (TED); organization is launch-ready -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526205010/d149508dex991.htm)) |
| June 30, 2026 | [Viridian Therapeutics, Inc.\DE PDUFA date](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | scheduled | "PDUFA target: June 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526205099/d20977dex992.htm)) |
| August 6, 2026 | [Viridian Therapeutics, Inc.\DE earnings report](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed | "WALTHAM, Mass. - August 6, 2026 - Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526336691/d174744dex991.htm)) |
| August 13, 2026 | [Lumvoa™ (veligrotug) topline data readout](https://sec-api.dev/pdufa/veligrotug) | VRDN | Thyroid Eye Disease | completed | "NCT06384547 (A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-01 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.; Results First Posted 2026-08-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06384547?tab=results)) |
| Q4 2026 | [VRDN-292 trial start](https://sec-api.dev/pdufa/vrdn-292) | VRDN | Graves' disease | scheduled | "- VRDN-292, a potential best-in-class TSHR inhibitor, expected to initiate a phase 1 clinical trial in patients in Q4 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526446200/d176865dex991.htm)) |
| November 4, 2026 | [Viridian Therapeutics, Inc.\DE earnings report](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed | "Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526446200/d176865dex991.htm)) |
| Q1 2027 | [Elegrobart NDA/BLA submission](https://sec-api.dev/pdufa/elegrobart) | VRDN | chronic TED | scheduled | "Our pipeline also continues to move forward as we advance elegrobart, our subcutaneously administered anti-IGF-1R, toward a planned BLA submission for TED in the first quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526446200/d176865dex991.htm)) |
| Q1 2027 | [Lumvoa™ (veligrotug) NDA/BLA submission](https://sec-api.dev/pdufa/veligrotug) | VRDN |  | scheduled | "Viridian's expectations regarding the anticipated timing or likelihood of regulatory submissions and approvals, including the anticipated approval of the BLA for veligrotug and the anticipated submission of a BLA for elegrobart in Q1 2027;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526205099/d20977dex991.htm)) |
| mid-2027 | [VRDN-008 trial start](https://sec-api.dev/pdufa/vrdn-008) | VRDN |  | scheduled | "Rapid path to BLA, starting in MG: Viridian plans to initiate a registrational trial in MG with VRDN-008 in mid-2027, pending regulatory feedback." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526452665/d106932dex991.htm)) |
| 2H 2027 | [Lumvoa™ (veligrotug) NDA/BLA submission](https://sec-api.dev/pdufa/veligrotug) | VRDN |  | scheduled | "- Strong cash position of $753 million as of September 30, 2024; provides cash runway into the second half of 2027 through the anticipated commercial launch of veligrotug, topline results and BLA submission for subcutaneous VRDN-003, and multiple FcRn inhibitor clinical catalysts -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312524279021/d648282dex991.htm)) |

## Drugs

- [Elegrobart](https://sec-api.dev/pdufa/elegrobart): chronic ted, chronic thyroid eye disease, active thyroid eye disease
- [Lumvoa™ (veligrotug)](https://sec-api.dev/pdufa/veligrotug): thyroid eye disease, ted in june 2026, ted regardless of activity or duration, chronic thyroid eye disease, chronic ted
- [Lumvoa (veligrotug-vvze)](https://sec-api.dev/pdufa/veligrotug-vvze): To treat thyroid eye disease
- [VRDN-003](https://sec-api.dev/pdufa/vrdn-003): Thyroid Eye Disease, Thyroid Eye Disease (TED)
- [VRDN-006](https://sec-api.dev/pdufa/vrdn-006): 
- [VRDN-008](https://sec-api.dev/pdufa/vrdn-008): 
- [VRDN-292](https://sec-api.dev/pdufa/vrdn-292): graves' disease

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/vrdn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VRDN catalysts: Viridian Therapeutics, Inc.\DE PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/vrdn/catalysts

```bibtex
@misc{secapidev_companies_vrdn_catalysts_20261116,
  title        = {VRDN catalysts: Viridian Therapeutics, Inc.\DE PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/vrdn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_vrdn_catalysts_20261116","title":"VRDN catalysts: Viridian Therapeutics, Inc.\\DE PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/vrdn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
